• Ready to Network at the HCP 2018 Spring Hospital Pharmacy Conference

    Justin Rolling and Rhodie Smith are attending the Health Connect Partners (HCP) 2018 Spring Hospital Pharmacy Conference April 30 – May 2 in Atlanta and representing RxStrategies. Here, America’s most prestigious hospitals and health systems will come together to gain industry-leading insight and education and network through the two Reverse EXPO sessions. Be sure to… Read more »

  • Stay on Top of 340B with Split Billing

    RxStrategies recognizes the complexities of 340B program management and offers solutions to better ensure proper management and program compliance. With our Split Billing Solution, you can: Review prescription activity Flag eligible 340B dispenses Designate activity for proper replenishment Audit and report GPO, WAC and 340B With customized reporting, onsite audit support, order confirmations, pharmacy system… Read more »

  • Clinical Insights: April 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV… Read more »

  • Clinical Insights: March 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval IlumyaTM (tildrakizumab-asmn) – New Drug Approval – March 21, 2018 – Sun Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved… Read more »

  • Integrated Solutions to Maintain Program Compliance

    There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance.   Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses.   CompliancePlus Streamlines workflow, quickly indemnifies… Read more »

  • Stay Ahead of the Game at NACHC’s P&I 2018!

    March 14-17, RxStrategies team members Rhodie Smith and Justin Rolling will be in Washington, D.C. for the National Association of Community Health Centers’ (NACHC) 2018 Policy and Issues Forum. Here, industry leaders will gather to offer unique insight to Members of Congress while offering solutions to current program regulations and legislative issues. Stay ahead of… Read more »

  • Clinical Insights: February 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®… Read more »

  • Make Your Appointment Now!

    The 340B Coalition Winter Conference in San Diego, California is coming up in exactly two weeks! Don’t forget to make your appointment with our team at RxStrategies to discuss solutions to support program compliance and view our 340B CompliancePlus Demo or Dashboard Analytics Demo. Schedule a demo for the conference » Visit Booth #227/326 at… Read more »

  • Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »